Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $48.57M (cash outflow) rose 64.7% year over year, behind the +441.4% change in trailing-twelve-month net income. Sequentially, it fell 65.6% from the prior quarter.

Context

  • Net income amounted to 102.0% of revenue in FY2025, up 92.5 pp from a year earlier.
  • Net income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$148.74M (-32.5%) for the fiscal year ending Dec 2026, a slowdown from the +1066.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$48.57M-65.6% QoQ
Last fiscal yearDec 2025
-$220.47M+1066.5% YoY
LTMMar 2026
-$239.55M+441.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+64.7%+29.5%-35.2 pp
1 year+1066.5%-32.5%-1099.1 pp
3-year CAGR—-41.3%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(220.47M) USD
Year-over-year change
-1066.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 net income of $239.55M is the 2nd largest of the 11 companies compared; the peer median is $107.11M.
  • Its year-over-year change of +441.4% is the 2nd highest of 11, against a peer median of +14.0%.
  • Net income amounts to 110.0% of revenue for VNDA, versus a peer median of 1607.3%.
VNDA Competitors Peer median
Net Income for VNDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$80.71B +146477.0%+53.5%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$239.55M +441.4%—110.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M -31.1%-16.9%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$169.52M +21.5%+11.0%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$166.12M -770.3%+15.0%2895.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$116.64M +37.7%+37.1%319.6%
HUMAHumacyte, Inc.LTM Mar 2026$97.59M +25.7%+50.6%4840.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M +15.4%—173.5%
IMRXImmuneering CorporationLTM Mar 2026$54.44M -11.9%+3.5%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$51.99M +12.6%+8.9%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$43.51M -23.8%+18.7%—
Peer median (excluding VNDA) $107.11M+14.0%+15.0%1607.3%

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Depreciation & Amortization2.84M2.73M3.01M8.13M(950K)
Deferred Income Tax6.75M1.13M(1.29M)(6.48M)81.44M
Stock-Based Compensation15.37M16.28M14.04M12.43M9.47M
Change in Working Capital2.74M6.07M(747K)(6.56M)8.31M
Accounts Receivables(2.47M)(1.09M)(707K)(13.01M)(7.46M)
Inventory(2.23M)(4.48M)(771K)(29K)(3.47M)
Accounts Payables3.04M11.79M(10.98M)1.71M15.82M
Other Working Capital4.4M(151K)11.72M4.78M3.42M
Other Non-Cash Items3.37M(507K)(4.73M)(4.38M)12.76M
Operating Cash Flow64.21M31.98M12.8M(15.76M)(109.44M)
Capital Expenditures(552K)(679K)(383K)(490K)(998K)
Acquisitions (Net)00(100.67M)(4.23M)0
Purchases of Investments(420.46M)(349.26M)(512.61M)(364.77M)(112.38M)
Sales of Investments344.32M399.86M601.6M352.06M208.24M
Other Investing Activities00000
Investing Cash Flow(76.7M)49.93M(12.06M)(17.43M)94.86M
Debt Repayment000(155K)(1.99M)
Common Stock Issued3.55M734K000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000(915K)
Financing Cash Flow3.55M734K0(155K)(2.91M)
Effect of Forex Changes(85K)315K47K(163K)126K
Net Change in Cash(9.02M)82.96M792K(33.51M)(17.36M)
Free Cash Flow63.66M31.31M12.42M(16.25M)(110.44M)

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.